Allie Nawrat

You can get in touch with Allie on Alexandra.Nawrat@verdict.co.uk

All articles by Allie Nawrat

1. Janssen’s Tremfya shows superiority in plaque psoriasis to Novartis’ drug at 48 weeks

   Johnson & Johnson subsidiary Janssen has announced results from its phase III Eclipse trial comparing its Tremfya (guselkumab) with Novartis’…
   Read More…

   13 Dec
2. Incretin combination therapy: a breakthrough for type 2 diabetes?

   Despite being one of the most prevalent diseases in the world, diabetes, and particularly type 2 diabetes, remains a challenge…
   Read More…

   12 Dec
3. New Zealand moves towards legalising medical cannabis

   New Zealand’s parliament has passed an amendment to the Misuse of Drugs Act 1975 that will allow terminally ill patients…
   Read More…

   11 Dec
4. Gilead appoints current Roche Pharmaceuticals CEO as new CEO and chairman

   The board of directors at Gilead Sciences has announced it has chosen Daniel O’Day, the current CEO of Roche Pharmaceuticals…
   Read More…

   10 Dec
5. Mallinckrodt to spin off its speciality generics business next year

   After two years of planning, UK-based pharmaceutical company Mallinckrodt has announced plans to split its speciality generics and active pharmaceutical…
   Read More…

   7 Dec
6. AbbVie halts phase III TAHOE trial of Rova-T for SCLC

   Following advice from an independent data monitoring committee, biopharma company AbbVie has ceased enrolment in its TAHOE trial evaluating Rovalpituzumab…
   Read More…

   6 Dec
7. FDA agrees accelerated approval pathway for GBT’s voxelotor

   The US Food and Drug Administration (FDA) has granted San Francisco-based Global Blood Therapeutics (GBT)’s sickle cell disease (SCD) therapy…
   Read More…

   4 Dec
8. Will tech giants like Amazon and Google change the pharma sector forever?

   In June this year, the world’s first trillion dollar company Amazon announced it was acquiring online pharmacy business PillPack, following…
   Read More…

   4 Dec
9. WHO World Malaria Report 2018: stalling progress, but implementing new approach

   The World Health Organisation (WHO) publishes a World Malaria Report at the end of every year in which it provides…
   Read More…

   19 Nov
10. Aimmune publishes phase III data for peanut allergy drug

    Aimmune has published the data from its phase III PALISADE clinical trial into AR101, a biologic immunotherapy indicated for desensitisation…
    Read More…

    19 Nov